ScreenerHero

HELP Cybin D/B/A Helus Pharma

NAS · US · Healthcare · Biotechnology · helus.com
10.51USD-2.32%Mkt Cap: 767.96M $P/E: —

Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap767.96M USD
Enterprise Value619.76M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-148.00M USD
Revenue/Share—
Last Price10.51 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.04
PEG—
EV/EBITDA-3.71
EV/Revenue—
P/S—
P/B2.75
EPS (TTM)-4.15
EPS (Forward)-1.78
52W Range
3.76059% of range15.15
52W High15.15 USD
52W Low3.760 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-63.85%
ROA-58.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-133.27M USD
CapEx (TTM)1.37M USD
FCF Margin—
FCF Yield-10.73%
Net Debt-166.36M USD
Net Debt/EBITDA1.00
Balance Sheet
Debt/Equity—
Current Ratio10.97
Quick Ratio9.76
Book Value/Sh3.91 USD
Cash/Share2.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:38
Split DateSep 19, 2024
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.94 USD
Upside (mean)+280.0%
Target Range14.91 USD – 68.36 USD
14.91+280.0% to mean68.36
# Analysts10
Ownership
Shares Out.73.06M
Float58.04M
Insiders12.58%
Institutions41.10%
Short Interest
Short Ratio2.2d
Short % Out.4.42%
Shares Short3.23M
Short (prev mo.)3.20M
Technical
SMA 5011.74 (-10.5%)
SMA 2007.430 (+41.5%)
Beta0.54
S&P 52W Chg16.45%
Avg Vol (30d)1.58M
Avg Vol (10d)1.34M
Technical Indicators
RSI (14)37.3
MACD-0.1024
MACD Signal0.2836
MACD Hist.-0.3860
BB Upper14.34 USD
BB Middle12.52 USD
BB Lower10.70 USD
BB Width29.04%
ATR (14)0.8225 USD
Vol Ratio (20d)0.49x